Extended low-dose apixaban was investigated for its impact on symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism and enduring risk factors.
Does extended low-dose apixaban reduce symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors?
This post hoc analysis investigates whether extended low-dose apixaban impacts symptomatic superficial vein thrombosis events in patients with provoked VTE.
Absolute Event Rate: 0% vs 0%
This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism ( HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.
“Patients with acute VTE with transient provoking factors, such as surgery, trauma or immobility, typically receive short-term anticoagulation. However, the risk of VTE recurrence may remain high in certain patients with enduring risk factors, including those with obesity, chronic lung disease or autoimmune disorders. In such patients, the optimal duration of anticoagulation is uncertain. We designed the HI-PRO trial to assess the efficacy and safety of extended-duration apixaban 2.5 mg twice daily, compared with placebo, for the prevention of recurrence in patients with provoked VTE and at least one enduring risk factor.”
Rashedi et al. (Sun,) reported a other. Extended low-dose apixaban was investigated for its impact on symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism and enduring risk factors.